(VIANEWS) – Atmos Energy Corporation (ATO), Catalyst Pharmaceuticals (CPRX), Titan International (TWI) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Atmos Energy Corporation (ATO)
35.1% sales growth and 9.16% return on equity
Atmos Energy Corporation, together with its subsidiaries, engages in the regulated natural gas distribution, and pipeline and storage businesses in the United States. It operates in two segments, Distribution, and Pipeline and Storage. The Distribution segment is involved in the regulated natural gas distribution and related sales operations in eight states. This segment distributes natural gas to approximately three million residential, commercial, public authority, and industrial customers. As of September 30, 2020, it owned 71,558 miles of underground distribution and transmission mains. The Pipeline and Storage segment engages in the pipeline and storage operations. This segment transports natural gas for third parties and manages five underground storage reservoirs in Texas; and provides ancillary services to the pipeline industry, including parking arrangements, lending, and inventory sales. As of September 30, 2020, it owned 5,684 miles of gas transmission lines. Atmos Energy Corporation was founded in 1906 and is headquartered in Dallas, Texas.
Earnings Per Share
As for profitability, Atmos Energy Corporation has a trailing twelve months EPS of $6.63.
PE Ratio
Atmos Energy Corporation has a trailing twelve months price to earnings ratio of 17.49. Meaning, the purchaser of the share is investing $17.49 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.16%.
Moving Average
Atmos Energy Corporation’s worth is under its 50-day moving average of $116.80 and above its 200-day moving average of $114.13.
Yearly Top and Bottom Value
Atmos Energy Corporation’s stock is valued at $115.98 at 01:22 EST, under its 52-week high of $125.28 and way above its 52-week low of $101.00.
Previous days news about Atmos Energy Corporation(ATO)
- According to Zacks on Monday, 8 July, "Investors interested in the utilitysector might look at some better-ranked stocks like California Water Service Group (CWT Quick QuoteCWT – Free Report) andPrimo Water Corporation (PRMW Quick QuotePRMW – Free Report) , each sporting a Zacks Rank #1 (Strong Buy) and Atmos Energy Corporation (ATO Quick QuoteATO – Free Report) , holding a Zacks Rank #2 (Buy), at present. "
2. Catalyst Pharmaceuticals (CPRX)
20.5% sales growth and 14.55% return on equity
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
Earnings Per Share
As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.63.
PE Ratio
Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 24.16. Meaning, the purchaser of the share is investing $24.16 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.55%.
Sales Growth
Catalyst Pharmaceuticals’s sales growth for the next quarter is 20.5%.
3. Titan International (TWI)
20.3% sales growth and 11.43% return on equity
Titan International, Inc., together with its subsidiaries, manufactures and sells wheels, tires, and undercarriage systems and components for off-highway vehicles in the United States and internationally. The company operates in Agricultural, Earthmoving/Construction, and Consumer segments. It offers wheels, tires, and undercarriage systems and components for various agricultural equipment, including tractors, combines, skidders, plows, planters, and irrigation equipment. The company also offers wheels, tires, and undercarriage systems and components for off-the-road earthmoving, mining, military, construction, and forestry equipment, including skid steers, aerial lifts, cranes, graders and levelers, scrapers, self-propelled shovel loaders, articulated dump trucks, load transporters, haul trucks, backhoe loaders, crawler tractors, lattice cranes, shovels, and hydraulic excavators. In addition, it provides bias and light truck tires; and products for ATVs, rock climbers, and turf applications, as well as specialty products and train brakes. It sells its products directly to original equipment manufacturers, as well as to the aftermarket through independent distributors, equipment dealers, and its distribution centers. Titan International, Inc. was founded in 1890 and is headquartered in West Chicago, Illinois.
Earnings Per Share
As for profitability, Titan International has a trailing twelve months EPS of $0.89.
PE Ratio
Titan International has a trailing twelve months price to earnings ratio of 7.81. Meaning, the purchaser of the share is investing $7.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.43%.
Volume
Today’s last reported volume for Titan International is 752140 which is 9.88% above its average volume of 684480.
Yearly Top and Bottom Value
Titan International’s stock is valued at $6.95 at 01:22 EST, way under its 52-week high of $15.33 and higher than its 52-week low of $6.71.
Sales Growth
Titan International’s sales growth is 13.7% for the ongoing quarter and 20.3% for the next.
4. FNF Group of Fidelity National Financial (FNF)
18.3% sales growth and 12.08% return on equity
Fidelity National Financial, Inc., together with its subsidiaries, provides various insurance products in the United States. The company operates through Title, F&G, and Corporate and Other segments. It offers title insurance, escrow, and other title related services, including trust activities, trustee sales guarantees, recordings and reconveyances, and home warranty insurance. The company also provides technology and transaction services to the real estate and mortgage industries; and mortgage transaction services, including title-related services and facilitation of production and management of mortgage loans. In addition, it offers annuity and life insurance products, such as deferred annuities that include fixed indexed, fixed rate, and immediate annuities, as well as indexed universal life insurance products. Further, the company engages in the real estate brokerage business. Fidelity National Financial, Inc. was founded in 1847 and is headquartered in Jacksonville, Florida.
Earnings Per Share
As for profitability, FNF Group of Fidelity National Financial has a trailing twelve months EPS of $3.04.
PE Ratio
FNF Group of Fidelity National Financial has a trailing twelve months price to earnings ratio of 16.23. Meaning, the purchaser of the share is investing $16.23 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.08%.
Moving Average
FNF Group of Fidelity National Financial’s value is below its 50-day moving average of $50.35 and above its 200-day moving average of $47.73.
5. Middlesex Water Company (MSEX)
14.6% sales growth and 8.7% return on equity
Middlesex Water Company owns and operates regulated water utility and wastewater systems. It operates in two segments, Regulated and Non-Regulated. The Regulated segment collects, treats, and distributes water on a retail and wholesale basis to residential, commercial, industrial, and fire protection customers in parts of New Jersey, Delaware, and Pennsylvania. This segment also includes regulated wastewater systems in New Jersey and Delaware. The Non-Regulated segment provides non-regulated contract services for the operation and maintenance of municipal and private water and wastewater systems in New Jersey and Delaware. The company was incorporated in 1896 and is headquartered in Iselin, New Jersey.
Earnings Per Share
As for profitability, Middlesex Water Company has a trailing twelve months EPS of $2.02.
PE Ratio
Middlesex Water Company has a trailing twelve months price to earnings ratio of 25.45. Meaning, the purchaser of the share is investing $25.45 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.7%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.2%, now sitting on 168.64M for the twelve trailing months.
Sales Growth
Middlesex Water Company’s sales growth is 15.4% for the current quarter and 14.6% for the next.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 14, 2024, the estimated forward annual dividend rate is 1.3 and the estimated forward annual dividend yield is 2.53%.
6. LeMaitre Vascular (LMAT)
10.4% sales growth and 11.65% return on equity
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers restoreflow allografts; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access in patients with or without a previously-failed synthetic graft; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular and cardiac patches, which are used for closure of vessels after surgical intervention; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Earnings Per Share
As for profitability, LeMaitre Vascular has a trailing twelve months EPS of $1.51.
PE Ratio
LeMaitre Vascular has a trailing twelve months price to earnings ratio of 53.97. Meaning, the purchaser of the share is investing $53.97 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.65%.
Moving Average
LeMaitre Vascular’s worth is way above its 50-day moving average of $73.97 and way higher than its 200-day moving average of $61.48.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 15, 2024, the estimated forward annual dividend rate is 0.64 and the estimated forward annual dividend yield is 0.79%.
Yearly Top and Bottom Value
LeMaitre Vascular’s stock is valued at $81.50 at 01:22 EST, under its 52-week high of $84.15 and way above its 52-week low of $44.27.
7. Horace Mann Educators Corporation (HMN)
9.4% sales growth and 5.52% return on equity
Horace Mann Educators Corporation, together with its subsidiaries, operates as an insurance holding company in the United States. It operates in three segments: Property & Casualty, Life & Retirement, and Supplemental & Group Benefits. The company underwrites and markets personal lines of property and casualty insurance, including personal lines auto and property insurance products; supplemental insurance products, which include cancer, heart, hospital, supplemental disability, and accident coverages; retirement products, such as tax-qualified fixed and variable annuities; and life insurance products comprising whole life and term, as well as indexed universal life insurance products. It also offers student loan solutions, including online student loan management accounts for educators. The company markets its products through its sales force of full-time exclusive agents to K-12 teachers, administrators, and other employees of public schools and their families. Horace Mann Educators Corporation was founded in 1945 and is headquartered in Springfield, Illinois.
Earnings Per Share
As for profitability, Horace Mann Educators Corporation has a trailing twelve months EPS of $1.57.
PE Ratio
Horace Mann Educators Corporation has a trailing twelve months price to earnings ratio of 20.46. Meaning, the purchaser of the share is investing $20.46 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.52%.
8. CBIZ (CBZ)
7.8% sales growth and 15.22% return on equity
CBIZ, Inc. provides financial, insurance, and advisory services in the United States and Canada. The company operates through three segments: Financial Services, Benefits and Insurance Services, and National Practices. The Financial Services segment offers accounting and tax, government healthcare consulting, financial advisory, valuation, and risk and advisory services. The Benefits and Insurance Services provides group health benefits consulting, payroll, property and casualty, and retirement plan services. The National Practices segment offers managed networking and hardware, and health care consulting services. It primarily serves small and medium-sized businesses, as well as individuals, governmental entities, and not-for-profit enterprises. The company was founded in 1987 and is headquartered in Cleveland, Ohio.
Earnings Per Share
As for profitability, CBIZ has a trailing twelve months EPS of $2.48.
PE Ratio
CBIZ has a trailing twelve months price to earnings ratio of 29.71. Meaning, the purchaser of the share is investing $29.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.22%.
Volume
Today’s last reported volume for CBIZ is 302988 which is 6.2% above its average volume of 285285.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 28.3% and 9%, respectively.
Yearly Top and Bottom Value
CBIZ’s stock is valued at $73.69 at 01:22 EST, under its 52-week high of $80.42 and way above its 52-week low of $49.15.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8.7%, now sitting on 1.63B for the twelve trailing months.
